Search results
Results from the WOW.Com Content Network
Stocks of coronavirus vaccine could run out at the end of January unless new ones such as the Oxford jab are approved, a former minister has warned. Former health secretary Jeremy Hunt told the ...
Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on two other candidates. One is an investigational influenza vaccine.
The company — which expects its 2023 revenus to be at least $6 billion — reported $1.8 billion in COVID-19 vaccine sales in the third quarter and $3.9 billion through Q3.
On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, ... Pfizer stock has dipped 11%, and ...
Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19
For premium support please call: 800-290-4726 more ways to reach us
As the omicron variant picks up speed, investors are turning to vaccine stocks that could potentially profit. The U.S. is currently averaging 121,107 new Covid-19 cases per day and showing no ...